Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Zelira Therapeutics ( (AU:ZLD) ) has shared an announcement.
Zelira Therapeutics announced that its Managing Director, Dr. Oludare Odumosu, and Non-Executive Director, Dr. Donna Gentile O’Donnell, will provide a total of USD$150,000 in unsecured loan notes to the company. These funds will be used for general working capital purposes. The loan notes, subject to shareholder approval, may be converted into shares at a premium price, reflecting favorable terms for the company amidst current market conditions. This strategic financial move is expected to bolster Zelira’s operational capabilities and strengthen its market position.
The most recent analyst rating on (AU:ZLD) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.
More about Zelira Therapeutics
Zelira Therapeutics is a global leader in the development of clinically validated cannabis medicines, focusing on creating innovative therapeutic solutions. The company operates in the pharmaceutical industry, with a market focus on cannabis-based treatments.
Average Trading Volume: 2,626
Technical Sentiment Signal: Sell
Current Market Cap: A$4.88M
For a thorough assessment of ZLD stock, go to TipRanks’ Stock Analysis page.